Hanmi Pharm Gains Global Attention with Next-Generation Obesity Treatment 'HM15275'
상태바
Hanmi Pharm Gains Global Attention with Next-Generation Obesity Treatment 'HM15275'
  • BK Min
  • 승인 2024.06.26 13:45
  • 댓글 0
이 기사를 공유합니다

Hanmi Pharmaceutical(Hanmi) has garnered global attention by unveiling the preclinical research results of its triple-action obesity treatment (LA-GLP/GIP/GCG, code-named HM15275) at the American Diabetes Association (ADA) meeting. The new drug, expected to achieve over 25% weight loss with minimal muscle loss, is recognized as a next-generation obesity treatment.

From June 21 to 24, at the ADA 2024 conference in Orlando, Florida, Hanmi presented the weight-loss efficacy and development strategy of HM15275. This drug, utilizing Hanmi's sustained-release platform technology, 'Acylation,' optimizes the actions of three receptors: glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP), and glucagon (GCG).

HM15275 has demonstrated weight loss effects comparable to bariatric surgery, confirming its potential as a 'Best-in-Class' new drug in obesity treatment. While existing GLP-1-based drugs show a 15-20% weight loss effect, HM15275 aims for a 25-30% reduction.

Researchers from Hanmi Pharmaceutical's R&D Center are using a poster presentation to explain the key research findings of the next-generation triple-action obesity treatment, HM15275, to attendees at the American Diabetes Association (ADA) conference.
Researchers from Hanmi Pharmaceutical's R&D Center are using a poster presentation to explain the key research findings of the next-generation triple-action obesity treatment, HM15275, to attendees at the American Diabetes Association (ADA) conference.

Hanmi announced that repeated administration of HM15275 in obesity models resulted in superior weight reduction compared to existing treatments. This is attributed to the drug's optimized triple pharmacological action, which controls diet and increases energy metabolism. Additionally, HM15275 has shown efficacy in treating various metabolic diseases, including cardiac hypertrophy, heart failure, and kidney diseases.

The drug exhibited excellent cardioprotective effects in conditions of cardiac hypertrophy and fibrosis due to hypertension and significantly improved exercise capacity in various heart failure models. It also demonstrated direct therapeutic effects on cardiomyocytes and cardiac fibroblasts, positively impacting cardiovascular disease beyond metabolic improvements.

Furthermore, HM15275 improved kidney function and reduced fibrosis in various disease models by directly acting on podocytes and renal proximal tubular epithelial cells. In May, Hanmi received approval from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of HM15275 and began patient enrollment in mid-June, with the first dosing already completed.

Choi In-young, head of Hanmi Pharmaceutical's R&D Center, stated, "This year's ADA presentation is significant as it marks the first international showcase of our 'next-generation obesity drug,' solidifying our leading position in the obesity treatment field." Hanmi Pharmaceutical plans to reveal a new obesity treatment pipeline with a novel non-incretin mechanism later this year.

The summary of this article in Korean is as follows.

▷한미약품, 차세대 비만치료제 'HM15275'로 주목

한미약품이 미국 당뇨병학회(ADA)에서 차세대 비만치료제 'HM15275'의 비임상 연구 결과를 공개해 세계적 주목을 받았다. HM15275는 25% 이상의 체중 감량 효과를 기대할 수 있으며, 근 손실을 최소화한다. 

기존 약물보다 우수한 체중 감소 효능과 심장, 신장 질환 등 다양한 대사성 질환에 효과를 보였다. 한미약품은 FDA 승인 후 임상 1상 시험을 시작했다. 최인영 R&D센터장은 이번 발표가 '차세대 비만 신약'의 국제적 인정을 의미한다고 밝혔다.

By_BK Min, KDFN
kdf@kdfnews.com

 


관련기사
더보기+

주요기사
댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.